A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris

Trial Profile

A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2016

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics
  • Acronyms MUSE
  • Most Recent Events

    • 12 Jul 2016 According to a Leo Pharma media release, following the results from from this MUSE study and a phase III PSO-FAST trial (Profile 233523) the company has launched Enstilar foam spray for psoriasis in the United Kingdom.
    • 26 Apr 2016 According to Leo Pharma media release, based on the results from this MUSE study and other PSO-FAST trial (see CTP 700233523), the company received marketing authorisation for Enstilar (calcipotriol/betamethasone dipropionate) for the topical treatment of plaque psoriasis in patients 18 years of age or older, in the United Kingdom.
    • 21 Mar 2016 According to a LEO Pharma media release, calcipotriol/betamethasone dipropionate (Enstilar) was approved for the treatment of plaque psoriasis by the US FDA in October 2015, and it received marketing approval in the EU in March 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top